HC Wainwright Has Bearish Estimate for ABEO Q4 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities researchers at HC Wainwright cut their Q4 2027 EPS estimates for shares of Abeona Therapeutics in a research note issued to investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.01) per share for the quarter, down from their previous forecast of $0.01. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.92) per share.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.12). The company had revenue of $11.38 million for the quarter, compared to the consensus estimate of $12.24 million.

A number of other equities analysts have also recently commented on ABEO. Weiss Ratings cut Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Oppenheimer reiterated an “outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a research note on Friday, August 14th. Finally, Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $19.33.

Abeona Therapeutics Trading Down 0.5%

Shares of Abeona Therapeutics stock opened at $6.06 on Tuesday. Abeona Therapeutics has a 1-year low of $4.00 and a 1-year high of $7.65. The company’s fifty day simple moving average is $6.38 and its 200-day simple moving average is $5.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.40. The stock has a market capitalization of $346.51 million, a PE ratio of -5.56 and a beta of 1.35.

Insider Activity at Abeona Therapeutics

In other news, Director Leila Alland sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $5.92, for a total value of $65,120.00. Following the completion of the sale, the director owned 162,614 shares in the company, valued at approximately $962,674.88. This trade represents a 6.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brendan M. O’malley sold 12,050 shares of Abeona Therapeutics stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $6.96, for a total transaction of $83,868.00. Following the transaction, the senior vice president directly owned 427,953 shares of the company’s stock, valued at approximately $2,978,552.88. This represents a 2.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 274,578 shares of company stock worth $1,674,433 in the last ninety days. Corporate insiders own 7.10% of the company’s stock.

Institutional Trading of Abeona Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in Abeona Therapeutics by 49.6% in the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 2,155 shares during the last quarter. Legato Capital Management LLC grew its stake in shares of Abeona Therapeutics by 21.0% during the fourth quarter. Legato Capital Management LLC now owns 13,180 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 2,290 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Abeona Therapeutics by 6.2% during the fourth quarter. Deutsche Bank AG now owns 39,368 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 2,303 shares during the last quarter. Rangeley Capital LLC raised its holdings in shares of Abeona Therapeutics by 4.2% in the first quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 2,400 shares during the period. Finally, LPL Financial LLC raised its holdings in shares of Abeona Therapeutics by 5.3% in the fourth quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 3,165 shares during the period. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.